In this randomized trial of patients undergoing transcatheter aortic valve replacement (TAVR), with an average of one severe coronary stenosis, percutaneous coronary intervention in addition to TAVR reduced the incidence of the combined endpoint of all-cause mortality, myocardial infarction, and urgent revascularization at two years.

ABSTRACT & COMMENTARY
PCI in TAVR Patients with Severe Coronary Lesions Shows Benefits
November 1, 2024